Source:http://linkedlifedata.com/resource/pubmed/id/19442806
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2009-5-15
|
| pubmed:commentsCorrections | |
| pubmed:language |
fre
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0151-9638
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
136
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
450-1
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
2009
|
| pubmed:articleTitle |
[Natalizumab and atypical naevi: Comments on the pharmacovigilance note by J.-L. Schmutz et al].
|
| pubmed:publicationType |
Letter,
Comment
|